Armed with the knowledge that the melanoma-associated antigen 4 (MAGE-A4) and the New York esophageal squamous cell carcinoma 1 (NY-ESO-1) are commonly expressed by ovarian cancer cells (26.4% and 3.6% respectively) (22), TCR-T products targeting these two ideal antigens have been designed and applied in clinical research. The gene discussed is MAGEA4; the disease is ovarian carcinoma.